Literature DB >> 11159302

Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge.

E Dompeling1, A M Oudesluys-Murphy, H M Janssens, W Hop, J G Brinkman, R N Sukhai, J C de Jongste.   

Abstract

BACKGROUND: Inhalation therapy using a pressured metered dose inhaler (pMDI) and a spacer is frequently used in the treatment of airway disease in children. Several laboratory studies found a clear negative influence of electrostatic charge (ESC) on plastic spacers on the delivery of aerosol. AIMS: To investigate whether ESC on plastic spacers could diminish bronchodilating responses to salbutamol.
METHODS: Ninety asthmatic children (aged 4-8 years) were randomised into three groups: metal Nebuchamber, plastic Volumatic, and plastic Aerochamber. The bronchodilating response was measured by the change in peak expiratory flow rate (PEF) after 100 microgram and 400 microgram salbutamol. Within the Volumatic and Aerochamber groups, a crossover comparison was made between electrostatic and non-electrostatic spacers.
RESULTS: We found no significant effect of ESC on the bronchodilating response to salbutamol with any of the doses in the Aerochamber and Volumatic groups. For the plastic spacers, the mean difference of the change in PEF after 100 microgram salbutamol between non-electrostatic and electrostatic spacers was only +1.7% (95% CI -1.3% to 4.7%). After 400 microgram salbutamol this was +1.9% (95% CI -1.4% to 5.1%). A comparable efficacy was found for the Nebuchamber, the Aerochamber, and Volumatic with respect to the change in PEF after 100 and 400 microgram salbutamol.
CONCLUSION: This study showed no negative influence of ESC on plastic spacers with regard to clinical efficacy of a beta(2) agonist (salbutamol) in children with asthma. The metal Nebuchamber, plastic Aerochamber, and plastic Volumatic were equally effective.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11159302      PMCID: PMC1718661          DOI: 10.1136/adc.84.2.178

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  23 in total

1.  Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery.

Authors:  F Piérart; J H Wildhaber; I Vrancken; S G Devadason; P N Le Souëf
Journal:  Eur Respir J       Date:  1999-03       Impact factor: 16.671

2.  Comparison of terbutaline via the Nebuhaler and salbutamol via the Volumatic: theory and practice.

Authors:  B J Chapman; G K Crompton
Journal:  Eur Respir J       Date:  1990-05       Impact factor: 16.671

3.  Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices.

Authors:  B J Lipworth; D J Clark
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

4.  A trial of metaproterenol by metered-dose inhaler and two spacers in preschool asthmatics.

Authors:  P König; D Gayer; A Kantak; C Kreutz; B Douglass; N L Hordvik
Journal:  Pediatr Pulmonol       Date:  1988

5.  The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients.

Authors:  C J Kenyon; L Thorsson; L Borgström; S P Newman
Journal:  Eur Respir J       Date:  1998-03       Impact factor: 16.671

Review 6.  The functional development of the respiratory system from the period of gestation to adulthood.

Authors:  G Polgar; T R Weng
Journal:  Am Rev Respir Dis       Date:  1979-09

7.  Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuations of drug.

Authors:  C O'Callaghan; J Lynch; M Cant; C Robertson
Journal:  Thorax       Date:  1993-06       Impact factor: 9.139

8.  Use of budesonide in severe asthmatics aged 1-3 years.

Authors:  G J Connett; C Warde; E Wooler; W Lenney
Journal:  Arch Dis Child       Date:  1993-09       Impact factor: 3.791

9.  Evaluation of inhalation aids of metered dose inhalers in asthmatic children.

Authors:  H Lee; H E Evans
Journal:  Chest       Date:  1987-03       Impact factor: 9.410

10.  A comparison of six different ways of expressing the bronchodilating response in asthma and COPD; reproducibility and dependence of prebronchodilator FEV1.

Authors:  E Dompeling; C P van Schayck; J Molema; R Akkermans; H Folgering; P M van Grunsven; C van Weel
Journal:  Eur Respir J       Date:  1992-09       Impact factor: 16.671

View more
  7 in total

1.  Aerosol profile extracted from spacers as a determinant of actual dose.

Authors:  Sylvia Verbanck; Chris Vervaet; Daniël Schuermans; Walter Vincken
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

Review 2.  A path to successful patient outcomes through aerosol drug delivery to children: a narrative review.

Authors:  Arzu Ari
Journal:  Ann Transl Med       Date:  2021-04

3.  Response to albuterol MDI delivered through an anti-static chamber during nocturnal bronchospasm.

Authors:  Sreekala Prabhakaran; Jonathan Shuster; Sarah Chesrown; Leslie Hendeles
Journal:  Respir Care       Date:  2012-02-17       Impact factor: 2.258

Review 4.  The use of inhaled corticosteroids in children with asthma.

Authors:  H William Kelly; Hengameh Heidarian-Raissy
Journal:  Curr Allergy Asthma Rep       Date:  2002-03       Impact factor: 4.806

Review 5.  Drug delivery interfaces: A way to optimize inhalation therapy in spontaneously breathing children.

Authors:  Arzu Ari
Journal:  World J Clin Pediatr       Date:  2016-08-08

Review 6.  Optimal administration of bronchodilators with valved holding chambers in preschool children: a review of literature.

Authors:  Péter Csonka; Terhi Tapiainen; Mika J Mäkelä; Lauri Lehtimäki
Journal:  Eur J Pediatr       Date:  2021-04-20       Impact factor: 3.183

Review 7.  A review of the in vitro and in vivo valved holding chamber (VHC) literature with a focus on the AeroChamber Plus Flow-Vu Anti-static VHC.

Authors:  Sanjeeva Dissanayake; Jason Suggett
Journal:  Ther Adv Respir Dis       Date:  2018 Jan-Dec       Impact factor: 4.031

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.